Comparator group – Page 3 – Communicable Diseases Research

Gender disparities in coronavirus disease 2019 clinical trial leadership

Original Article

Published on 2021-01-052022-10-04
Journal: Clinical microbiology and infection : the official [Category] 임상,

Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection

코로나19 의심환자 1054명 내원한 성인 1054명의 임상적 특징, 증상 및 결과: SARS-CoV-2 감염 여부 비교

Article

Published on 2020-12-012022-09-11
Journal: The Journal of Infection [Category] MERS, SARS, 진단, 치료기술,

[키워드] 95%CI Anosmia Atypical Bacteria Characteristics characteristics of patient clinical Clinical characteristics Cohort Comorbidities Comparator group COPD COVID-19 COVID-19 patient COVID-19 patients Ethnicity First wave healthcare healthcare worker Healthcare workers hospital hospitalised invasive ventilation Laboratory lack molecular MOST negative patients non-randomised trial outcome outcomes pandemic Patient patient data point-of-care positive presenting reported respiratory respiratory virus respiratory viruses RT-PCR SARS-CoV-2 SARS-COV-2 infection smoker Smokers Symptom Symptoms tested These data viruses was obtained white with COVID-19
[DOI] 10.1016/j.jinf.2020.09.033 PMC 바로가기 [Article Type] Article

Comparison of four COVID-19 screening strategies to facilitate early case identification within the homeless shelter population: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-11-232022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 90% power accompany addition All participant amplified applied blinded Canada Care city clinically Cluster collected Community comparator Comparator group computation computer-generated correlation COVID case COVID-19 COVID-19 testing detect detection rate dissemination Effectiveness eight element eligible envelope error rate estimate facilitate Frame Gender group homeless include information initial intervention arm intervention group Laboratory marker medium Nasopharyngeal swab nostril NPs nucleic acid number objective Older Open-label oral swab participant percentage performed positive prevention protocol Qualitative random assignment randomised controlled trial randomization randomize Randomized randomized trial receive recruitment regimen Registered Registration repeated required Respiratory illness RNase P RT-PCR Sample size SARS-CoV-2 Screening screening strategy secondary shelter specimen specimens Standard of care statistically significant status stratified study enrollment study period Study protocol Surveillance Swab swab sample swabs Symptom symptomatic participant Symptoms tongue transported Trial type I UTR verbal viral inactivation website
[DOI] 10.1186/s13063-020-04890-2 PMC 바로가기 [Article Type] Letter

Letter to the editor: Study Summary – Randomized Control Trial of Omega-3 Fatty Acid Supplementation for the Treatment of COVID-19 Related Olfactory Dysfunction

Letter

Published on 2020-11-232022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 acid allergy ARMS blinded clinically suspected Comparator group computer-generated conducted Control COVID-19 COVID-19 patients criteria double-blinded drug enrolment evaluate fatty identification include Infection intervention group laboratory-confirmed Medicine Mount Sinai nasal number objective Oil olfactory dysfunction omega-3 omega-3 fatty acid outcome participant Patient Pharmacy Placebo placebo-controlled trial Primary outcome protocol randomised randomised controlled trial Randomized receive Registered researcher Sample size School sequence Smell Smell loss status subject Test therapeutic Treatment Trial Version website with COVID-19
[DOI] 10.1186/s13063-020-04905-y PMC 바로가기 [Article Type] Letter

Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-11-022022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 28-day mortality accompany acute lung injury adverse event airway All participant allergic anti-COVID19 IVIG Anti-viral Antibiotics assigned assisted ventilation autoimmune disorder blinded Blood oxygen saturation blood pressure C-IVIG Care Clinical efficacy Comparator group convalescent plasma COVID-19 COVID19 criteria Critically ill Critically ill patient CRP current disorder dosage Dyspnea excluded Follow-up four group group hemodynamic hemolytic anemia hospital hospital discharge Hospital stay hypersensitivity ICU IgA deficiency Ill immunization Immunoglobulin include infected individual Inflammation information inotropic agent Intervention intervention arm Isolation Karachi kidney Kidney failure lung infiltrate maintain Manifestations medication Meningitis MONITOR multiple organ dysfunction nasopharyngeal neutrophil lymphocyte ratio number objective observé oropharyngeal swabs outcome PaO parallel-group participant Passive passive immunization Patient patients positive SARS-CoV-2 PCR pregnant females Primary outcome protocol randomised randomised controlled randomised controlled trial randomization receive recruited Registered reported Respiratory failure respiratory rate Sample size sealed Septic shock shifting single dose standard care status Steroids Study protocol Support symptoms of COVID-19 therapy thromboembolic Total Treatment Trial university website were excluded with COVID-19
[DOI] 10.1186/s13063-020-04839-5 PMC 바로가기 [Article Type] Letter

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Article

Published on 2020-11-022022-10-30
Journal: Nutrients [Category] COVID-19, SARS,

[키워드] acute phase Admission age baseline Better Cancer Cardiomyopathy Clinical improvement Comparator group confounder Corticosteroids COVID-19 COVID-19 diagnosis COVID-19 patients determine diagnosis of COVID-19 effective elderly functional Gender group hazard ratio Health hemoglobin highest hospital Hospitalized hypertension involved less lower risk Mortality no difference Odds ratio Older adults participant Patient pharmacological treatment Potential proportion Quasi-experimental study Regular respiratory disorders SARS-CoV-2 severe COVID-19 survival survived survivor Therapeutics three group Treatment use of antibiotics Vitamin D vitamin D supplement Vitamin D supplementation while women
[DOI] 10.3390/nu12113377 PMC 바로가기 [Article Type] Article

The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial

입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-132022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] Alanine Alanine transaminase alcoholism All participant All participants allergies allergy allocation approved ARMS aspartate Aspartate transaminase assigned assumption Bandar Abba Bandar Abbas baseline Blinding block randomization blood count Care Chronic kidney disease clearance clinical clinical trial clinical trials code Committee company comparator Comparator group complete blood count concealed control group control groups COVID-19 COVID-19 patient COVID-19 patients creatinine creatinine clearance criteria Dasatinib dialysis discharge dissemination dosage drug therapy electrocardiogram element eligibility criteria End-stage renal disease ethics committee Evidence evidence of excluded expected Famotidine G6PD Glucose Glucose 6 phosphate grouping groups Hepatitis hepatitis C Hospitalized Immunocompromised Immunocompromised patients Infection Intervention Kidney disease Lactate lactate dehydrogenase lead limit Liver disease Local lung infiltration maximum Medical Science Medical Sciences moderate need for dialysis Neratinib normal limit number objective online tool oral contraceptives outcome outcome assessor outcome assessors oxygen oxygen saturation Ozanimod participant Patient patients patients with COVID-19 Pazopanib PCR test pharmaceutical Pharmaceutical Company phosphate Placebo placebo-controlled porphyria positive Pregnancy protocol psoriasis random randomisation randomised randomised controlled trial randomized clinical trial Randomly randomly divided receive recruitment Registered registry renal renal disease renal failure reported Research question researcher respiration rate responsible Rilpivirine Sample size sample size calculation sequence sequence information single-blind Siponimod Standard study drug Study protocol subject submitted technology temperature the ethics committee therapy title Tizanidine transaminase Treatment treatment group Treatment protocol treatment protocols Trial registration two group two groups university Version website were measured written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter

Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study

Protocol

Published on 2020-10-022022-10-29
Journal: JMIR Research Protocols [Category] COVID-19,

[키워드] 30-Day mortality antibodies antibody benefit blood donor both group Characteristics China clinically Cohort Comparator group Control control group convalescent plasma Coronaviruses COVID-19 COVID-19 pandemic CP infusion criteria detect Diagnosis disease Donor effective Efficacy expected feasibility Hospital stay Identifier immunology inclusion criteria Infectious disease initial interim analysis Interim report laboratory characteristics lack likelihood management Ministry of Health morbidity and mortality multicenter National objective outcome outcomes passive immunity Patient patients patients with COVID-19 phase propensity score matching protocol randomization Rapid test receive recipient recruited recruitment Registration Regulation report Result Safety SARS-CoV-2 SARS-CoV-2 antibody Saudi Arabia severe COVID-19 therapy total sample size transfusion treated Treatment two group Vaccine
[DOI] 10.2196/23543 PMC 바로가기 [Article Type] Protocol

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-09-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Ability Ability to walk Activation adhere administer ambulatory patient anatomical Anticoagulant treatment anticoagulation antiplatelet Atrial fibrillation baseline bleeding Blinding block size body temperature calculated Cardiovascular events characterized Chemotherapy clearance clinical benefit clinically Coagulation Coagulopathy Comorbidity Comparator group conducted contraindication control group coronary syndrome coronavirus cough COVID-19 creatinine criteria Critical current death defined diagnosed diagnosed with COVID-19 Diagnosis Disseminated intravascular coagulation dissemination dose Efficacy elderly element eligibility criteria eligible enoxaparin enrolment event event rate experimental group Face mask FIVE fixed heart failure help heparin-induced thrombocytopenia Hospitalization hospitals hygiene hypersensitivity impairment IMPROVE In-hospital Inflammation information injection inoperable Intervention intervention group invasive Ischemia Laboratory lack Last Liver disease lower limb major bleeding malignancy multicentre Myocardial number objective Older Open-label outcome parameter participant Participation Patient performed Platelet Positive test Presence prevention protocol provided Radiotherapy randomised randomised controlled trial randomization randomization ratio Randomized Randomized controlled trial receive reduce renal respiratory symptom resulting risk factor Sample size SARS-CoV2 secondary Seven Shortness of breath sore throat Spinal cord injury status Stratified randomization stroke Study protocol Support surgical survival symptomatic the patient therapy Thromboprophylaxis thrombosis total sample size Transport trauma Travel treated Treatment undergo university university hospital Venous Thromboembolism vessel viral disease VTE website
[DOI] 10.1186/s13063-020-04678-4 PMC 바로가기 [Article Type] Letter

Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials

Letter

Published on 2020-08-242022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] administration Analysis ARMS asked assessment Characteristics Chinese clinical trial Comparator group comparison Corticosteroid COVID-19 Critically ill patient defined Dexamethasone disease severity dissemination dose Effect element eligible EudraCT Evidence greater group heterogeneity High dose Hydrocortisone information Interaction Intervention intervention effect intervention group investigator ISRCTN less low dose meta-analyses Meta-analysis meta-regression Methylprednisolone Mortality Network meta-analysis objective Odds ratio Open-label outcome p-values participant Patient per day Placebo placebo-controlled primary analysis Prospective protocol provided quantified random-effect randomised controlled trial randomization Randomized Randomized controlled trials randomized trial Research Risk of bias RoB 2 secondary Serious Adverse Events Standard of care steroid Study protocol subgroup subgroups systematic review the WHO therapeutic dose therapy Treatment Trial trials usual care website WHO
[DOI] 10.1186/s13063-020-04641-3 PMC 바로가기 [Article Type] Letter